Treekitkarnmongkol, Katayama, Sankaran et al. identify RASH3D19 as a downstream target for KRAS signalling through miR-301a, which in turn leads to RAS activation and tumorigenesis. Targeting RASH3D19 inhibits growth of KRAS-mutant tumour cells in vivo.
- Warapen Treekitkarnmongkol
- Hiroshi Katayama
- Subrata Sen